166,153 Shares in GH Research PLC $GHRS Bought by CenterBook Partners LP

CenterBook Partners LP purchased a new stake in GH Research PLC (NASDAQ:GHRS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 166,153 shares of the company’s stock, valued at approximately $2,376,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stempoint Capital LP acquired a new stake in shares of GH Research during the 2nd quarter valued at about $1,229,000. AdvisorShares Investments LLC lifted its stake in GH Research by 41.1% during the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock worth $772,000 after purchasing an additional 15,735 shares during the period. HighVista Strategies LLC acquired a new position in shares of GH Research in the 2nd quarter worth approximately $637,000. BNP Paribas Financial Markets lifted its position in shares of GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of GH Research by 113.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 13,900 shares of the company’s stock worth $199,000 after buying an additional 7,400 shares during the period. 56.90% of the stock is owned by institutional investors.

GH Research Stock Performance

NASDAQ GHRS opened at $15.80 on Friday. The stock has a market capitalization of $822.07 million, a P/E ratio of -21.35 and a beta of 0.99. GH Research PLC has a 52 week low of $7.98 and a 52 week high of $19.51. The stock has a fifty day moving average of $14.85 and a 200-day moving average of $14.01.

Analyst Upgrades and Downgrades

GHRS has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price objective on GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Wolfe Research set a $39.00 price target on shares of GH Research in a report on Tuesday, January 6th. Citigroup reaffirmed a “market outperform” rating on shares of GH Research in a research note on Tuesday, January 6th. Wall Street Zen lowered shares of GH Research from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, HC Wainwright decreased their price target on GH Research from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.11.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.